Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMimetic Amends Augment Bone Graft PMA, Expects Approval By 2014

This article was originally published in The Gray Sheet

Executive Summary

BioMimetic Therapeutics submits PMA amendment for its Augment bone graft device to address questions raised by FDA in a “not approvable” letter disclosed in January.

You may also be interested in...



News Briefs: FDA Turns Down Wright’s Augment; Cook Resumes Zilver PTX Shipments; Luminex Restructures

Wright Medical receives not approvable letter for its Augment bone graft asking for another study. Judge rules against Zimmer in favor of Strkyer in patent case. Cook Medical has resolved the problems that triggered a December 2012 recall of its Zilver PTX peripheral stent. Luminex cuts staff, invests in molecular diagnostics efforts.

Wright Medical Augments Ortho Extremities Biz With BioMimetic Purchase

Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.

Deals Of The Week: Algeta/Ablynx, Pfizer/Cystic Fibrosis Foundation, Paladin/Ativa

Tryptophan-induced somnolence may be a side effect of Thanksgiving dinner, but the business week leading into Thanksgiving was not sleepy, as we were not short of deals to review.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT031381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel